Hematopoiesis News Volume 13.04 | Feb 1 2022

    By
    Justin.choi
    -
    0
    26







    2022-02-01 | HN 13.04


    Hematopoiesis News by STEMCELL Technologies
    Vol. 13.04 – 1 February, 2022
    TOP STORY

    An Oncogenic Enhancer Encodes Selective Selenium Dependency in AML

    By integrating comprehensive pan-cancer enhancer landscapes with genetic dependency mapping, investigators found that AML-enriched enhancers encoded for more selective tumor dependencies.
    [Cell Stem Cell]

    AbstractGraphical Abstract
    ON987CXN-feb-728x90-2022
    PUBLICATIONSRanked by the impact factor of the journal

    Loss of miR-31-5p Drives Hematopoietic Stem Cell Malignant Transformation and Restoration Eliminates Leukemia Stem Cells in Mice

    Researchers demonstrated a mechanism of HSC malignant transformation through altered energy metabolism and provided a potential therapeutic strategy to treat patients with AML.
    [Science Translational Medicine]

    Abstract

    Human Skin-Resident Host T Cells Can Persist Long Term after Allogeneic Stem Cell Transplantation and Maintain Recirculation Potential

    Analysis of 26 allogeneic HSC transplantation patients revealed profound interindividual variation in the tissue maintenance of host skin T cells.
    [Science Immunology]

    AbstractPress Release

    CAR T Cells Redirected to Cell Surface GRP78 Display Robust Anti-Acute Myeloid Leukemia Activity and Do Not Target Hematopoietic Progenitor Cells

    To target GRP78, scientists generated T cell expressing a GRP78-specific peptide-based chimeric antigen receptor (CAR), which showed evidence of minimal fratricide post activation/transduction and antigen-dependent T cell differentiation.
    [Nature Communications]

    Full Article

    Eltrombopag Inhibits TET Dioxygenase to Contribute to Hematopoietic Stem Cell Expansion in Aplastic Anemia

    TET inhibition in TET2 mutant malignant myeloid cells prevented neoplastic clonal evolution, in vitro and in vivo. This new mechanism of action may offer a restorative therapeutic index and provide a scientific rationale to treat selected patients with TET2-mutant or TET deficiency associated myeloid malignancies.
    [Journal of Clinical Investigation]

    AbstractFull ArticleGraphical Abstract

    Clinico-Biological Features of T Cell Acute Lymphoblastic Leukemia with Fusion Proteins

    An RT-MPLA assay was applied to a consecutive series of 522 adult and pediatric T cell acute lymphoblastic leukemias and identified a fusion transcript in 20% of cases.
    [Blood Cancer Journal]

    Full Article

    CDK12 Activates MYC to Repress miR-28-5p/EZH2 and Amplifies Tonic BCR Signaling to Promote the Development of Diffuse Large B Cell Lymphoma

    Cyclin-dependent kinase 12 (CDK12) activated MYC to repress miR-28-5p/EZH2 and amplified tonic BCR signaling to promote the development of diffuse large B cell lymphoma (DLBCL), which might provide potential therapeutic targets for future therapeutic intervention in DLBCL.
    [Cancer Gene Therapy]

    Abstract

    Evi1 Involved in Benzene-Induced Hematotoxicity via Modulation of PI3K/mTOR Pathway and Negative Regulation Serpinb2

    Researchers found that benzene exposure significantly increased ecotropic virus integration site-1 (Evi1) level in white blood cells in occupational benzene workers as well as mouse bone marrow cells.
    [Chemico-Biological interactions]

    Full ArticleGraphical Abstract

    Azacitidine-Induced Reconstitution of the Bone Marrow T Cell Repertoire Is Associated with Superior Survival in AML Patients

    Since hypomethylating agents possessed immunomodulatory functions that constituted part of their anti-tumor effect, the authors set out to analyze the bone marrow immune environment by next-generation sequencing of T cell receptor beta repertoires in 51 AML patients treated within the RAS-AZIC trial.
    [Blood Cancer Journal]

    Full Article

    Autologous NK Cells as Consolidation Therapy Following Stem Cell Transplantation in Multiple Myeloma

    Investigators demonstrated the feasibility of infusing multiple doses of ex vivo activated and expanded autologous NK cells in patients with multiple myeloma post-autologous stem cell transplantation.
    [Cell Reports Medicine]

    Full ArticleGraphical Abstract
    Free cell culture training with self-paced, on-demand courses.
    REVIEWS

    Clonal Expansion of Stem/Progenitor Cells in Cancer, Fibrotic Diseases, and Atherosclerosis, and CD47 Protection of Pathogenic Cells

    Scientists propose and demonstrate that myelogenous leukemia has a preleukemic phase. In the premalignant phase, normal HSCs gradually accumulate mutations leading to HSC clonal expansion, resulting in the emergence of leukemic stem cells.
    [Annual Review of Medicine]

    Abstract

    Single-Cell RNA Sequencing to Track Novel Perspectives in HSC Heterogeneity

    Investigators discuss how single-cell RNA sequencing technologies contribute to tracing origin and lineage commitment of HSCs, profiling the bone marrow microenvironment and providing high-resolution dissection of malignant hematopoiesis, leading to exciting new findings in HSC biology.
    [Stem Cell Research & Therapy]

    Full Article

    The Significance of CUX1 and Chromosome 7 in Myeloid Malignancies

    The authors discuss the clinical implications of del(7q) and CUX1 mutations, both in disease and clonal hematopoiesis, and synthesize recent literature on CUX1 and other chromosome 7 tumor suppressor genes.
    [Current Opinion in Hematology]

    Abstract
    INDUSTRY AND POLICY NEWS

    BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation

    BeiGene announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application for BeiGene’s BTK inhibitor BRUKINSA as a treatment for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    [BeiGene]

    Press Release
    FEATURED EVENT

    The Australasian Society for Stem Cell Research (ASSCR) Annual Meeting

    March 9 – 11, 2022
    Melbourne, Victoria, Australia

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Regenerative Medicine

    Stanford University – Stanford, California, United States

    Postdoctoral Scholar – Pediatric Hematology

    Penn State College of Medicine – Hershey, Pennsylvania, United States

    Faculty Position – Hematopathology

    University of Vermont – Burlington, Vermont, United States

    PhD Student – Chronic Lymphocytic Leukemia

    Luxembourg Institute of Health – Luxembourg, Luxembourg

    Postdoctoral Positions – Clinical Proteomics

    University of Copenhagen – Copenhagen, Denmark

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter